RxDoctor Payments Data

Michele Straka, DO

Obstetrics & Gynecology · Pittsburgh, PANPI 1770555021

Payments from drug & device makers

What this record shows

This record is dominated by education: $13,017 of the $19,691 with a category attached, or 66.1%. Intuitive Surgical accounts for 97.9% of it on its own, with 8 other manufacturers making up the rest. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,691in general payments, 2019–2025

Across 61 payments — averaging $322.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$19K
  • Mayne Pharma Commercial LLC$254
  • Conmed Corporation$56
  • GSK$27
  • Pacira Pharmaceuticals Incorporated$23
  • Pfizer$17
  • plus $45 from 3 others

What the payments were for

  • Speaking & faculty fees$5003%
  • Travel & lodging$3,42017%
  • Food & beverage$2,74414%
  • Education$13,01766%
  • Gifts$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,691 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

See all obstetrics & gynecology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,383
Medicare patients
69
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated44$18,049
GemtesaVibegron15$9,616
ImvexxyEstradiol13$4,319
Estradiol19$1,870
Estradiol (Twice Weekly)Estradiol11$1,235
ProgesteroneProgesterone, Micronized20$468
Clobetasol Propionate17$391
ValacyclovirValacyclovir Hcl14$318
Raloxifene Hcl11$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$17$18,04944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

Other obstetrics & gynecology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →